GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Status Recruiting

Clinical Trial Summary

This is a prospective clinical study to evaluate the safety and efficacy of GVM±R in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).

Clinical Trial Description

This is a single-arm, open label, multi-center clinical study to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome in combination with gemcitabine, vinorelbine and/or anti-CD20 monoclonal antibody(GVM ± R) in patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL).Mitoxantrone hydrochloride liposome will be given on day 1 at dose of 18 mg/m2 and be combined with gemcitabine, vinorelbine and/or rituximab (Pts with CD20-positive lymphomas are evaluated by the investigator on whether to combine rituximab or choose another CD20 monoclonal antibody).Each cycle consists of 21 days. A maximum of 6 cycles of therapy are planned. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06244368
Study type	Interventional
Source	Institute of Hematology & Blood Diseases Hospital, China
Contact	Wei Liu
Phone	022-23608461
Email	liuwei@ihcams.ac.cn
Status	Recruiting
Phase	Phase 2
Start date	January 17, 2024
Completion date	June 30, 2027

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT01804686` - A Long-term Extension Study of PCI-32765 (Ibrutinib)	Phase 3
Recruiting	`NCT05823701` - Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients	Phase 2
Completed	`NCT01691898` - A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)	Phase 1/Phase 2
Recruiting	`NCT03656835` - Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma	N/A
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Active, not recruiting	`NCT02060656` - Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)	Phase 2
Active, not recruiting	`NCT01653067` - STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma	Phase 2
Enrolling by invitation	`NCT00846157` - Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients	Phase 3
Completed	`NCT00440583` - The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP	Phase 2
Completed	`NCT01851551` - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL	Phase 1/Phase 2
Recruiting	`NCT04981795` - realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Completed	`NCT01186978` - Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma	N/A
Completed	`NCT01197560` - Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 2/Phase 3
Recruiting	`NCT03246906` - Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation	Phase 2
Not yet recruiting	`NCT05990985` - The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.	N/A
Completed	`NCT02890602` - Erythropoietin for Management of Anemia Caused by Chemotherapy	Phase 2
Completed	`NCT03630159` - Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients	Phase 1
Active, not recruiting	`NCT04529772` - A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)	Phase 3
Active, not recruiting	`NCT02900651` - Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies	Phase 1
Active, not recruiting	`NCT02481310` - Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma	Phase 1/Phase 2